| Literature DB >> 36060285 |
Rajeev Gupta1,2, Jitender S Makkar1, Sanjeev K Sharma1, Ansh Agarwal1, Krishna K Sharma3,4, Ajeet Bana5, Atul Kasliwal1, Sanjeev K Sidana1, Prem Ratan Degawat1, Kush K Bhagat1, Vishnu Natani3, Raghubir S Khedar2, Samin K Sharma1,6.
Abstract
Objective: Coronary artery disease (CAD) related hospitalization and interventions are associated with catastrophic out-of-pocket health expenditure in India. To evaluate differences in risk factors, disease severity, management and outcomes in uninsured vs insured CAD patients we performed a study.Entities:
Keywords: Coronary heart disease; Coronary interventions; Epidemiology; Health insurance; Social determinants of health
Year: 2022 PMID: 36060285 PMCID: PMC9434410 DOI: 10.1016/j.ijcrp.2022.200146
Source DB: PubMed Journal: Int J Cardiol Cardiovasc Risk Prev ISSN: 2772-4875
Fig. 1Proportion of Indian population potentially financially protected by various health insurance schemes (Data source: Reference 20).
Risk factors, clinical profile and outcomes in uninsured and insured (government and private) patients.
| Uninsured (n = 2166) | Government Insurance (n = 1635) | Private insurance (n = 871) | Statistics# (p value) | |
|---|---|---|---|---|
| Age mean (years) | 59.3 ± 11.2 | 61.8 ± 10.5 | 59.1 ± 10.2 | 31.14 (<0.001)* |
| ≤50y | 468 (21.6) | 229 (14.0) | 177 (20.3) | 25.9 (0.001) |
| 51-64y | 972 (44.9) | 764 (46.7) | 421 (48.3) | 1.21 (0.545) |
| ≥65y | 727 (33.6) | 642 (39.3) | 273 (31.3) | 9.55 (0.008) |
| Hypertension | 1137 (52.5) | 922 (56.4) | 521 (59.8) | 14.86 (0.001) |
| Diabetes | 817 (37.7) | 586 (35.8) | 367 (42.1) | 9.61 (0.008) |
| Cholesterol ≥200 mg/dl | 324 (15.0) | 113 (6.9) | 94 (10.8) | 60.2 (<0.001) |
| Non-HDL ≥ 130 mg | 700 (32.3) | 268 (16.4) | 216 (24.8) | 125.1 (<0.001) |
| Creatinine ≥2 mg | 46 (2.1) | 36 (2.2) | 16 (1.8) | 0.38 (0.826) |
| Smoking/tobacco | 295 (13.6) | 129 (14.0) | 75 (8.6) | 19.5 (<0.001) |
| Percutaneous coronary intervention | 262 (12.1) | 183 (11.2) | 117 (13.4) | 2.71 (0.258) |
| Coronary bypass surgery | 70 (3.2) | 53 (3.2) | 28 (3.2) | 0.001 (0.999) |
| Congestive heart failure | 12 (0.6) | 17 (1.0) | 10 (1.1) | 3.92 (0.140) |
| Acute coronary syndromes | 2055 (94.9) | 1569 (96.0) | 816 (93.7) | 0.16 (0.921) |
| STEMI | 953 (43.4) | 660 (42.1) | 282 (34.6) | 15.26 (0.001) |
| Non-STEMI/UAP | 1102 (53.6) | 909 (57.9) | 534 (65.4) | 8.28 (0.016) |
| Chronic coronary syndrome | 111 (5.1) | 66 (4.0) | 55 (6.3) | 5.84 (0.054) |
| Mean ejection fraction (EF) | 44.7 ± 10.2 | 45.4 ± 10.2 | 47.4 ± 9.7 | 21.80 (<0.001)* |
| EF <30% | 107 (5.0) | 66 (4.1) | 29 (3.4) | 4.04 (0.132) |
| EF 30–45% | 1213 (56.2) | 860 (53.5) | 386 (44.6) | 10.92 (0.004) |
| EF >45% | 838 (38.8) | 681 (42.4) | 450 (52.0) | 16.84 (0.001) |
| Aspirin | 699 (32.3) | 464 (28.4) | 295 (33.9) | 10.11 (0.006) |
| Beta-blockers | 563 (26.0) | 811 (49.6) | 324 (37.2) | 224.8 (<0.001) |
| Statins | 694 (32.0) | 969 (59.3) | 409 (47.0) | 282.7 (<0.001) |
| Elective | 1866 (86.1) | 1446 (88.2) | 760 (87.1) | 0.30 (0.861) |
| Emergency | 301 (13.9) | 193 (11.8) | 113 (12.9) | 2.78 (0.248) |
| Left main coronary artery | 127 (5.9) | 87 (5.3) | 53 (6.1) | 0.78 (0.677) |
| Right coronary artery | 1099 (50.7) | 756 (46.2) | 423 (48.6) | 7.57 (0.023) |
| Left anterior descending artery | 1731 (79.9) | 1244 (76.1) | 692 (79.4) | 8.68 (0.013) |
| Circumflex artery | 1059 (48.9) | 754 (46.1) | 419 (48.1) | 2.92 (0.252) |
| Single-vessel disease | 904 (41.7) | 781 (47.8) | 375 (43.1) | 5.46 (0.065) |
| Double vessel disease | 777 (35.9) | 556 (34.0) | 326 (37.4) | 1.49 (0.474) |
| Triple vessel disease | 477 (22.0) | 287 (17.6) | 169 (19.4) | 7.92 (0.019) |
| 1 | 1386 (64.0) | 1001 (61.2) | 537 (61.7) | 0.79 (0.673) |
| 2 | 575 (26.5) | 454 (27.8) | 239 (27.4) | 0.43 (0.806) |
| ≥3 | 163 (7.5) | 140 (8.6) | 83 (9.5) | 3.03 (0.219) |
| Aspirin | 2129 (98.3) | 1602 (98.0) | 850 (97.6) | 1.67 (0.433) |
| P2Y12 inhibitors | 2126 (98.2) | 1499 (91.7) | 824 (94.6) | 86.7 (<0.001) |
| Beta blockers | 1472 (68.0) | 1189 (72.7) | 611 (70.1) | 10.1 (0.006) |
| ACE inhibitors/ARBs | 1073 (49.5) | 780 (47.7) | 399 (45.8) | 3.71 (0.157) |
| Statins | 2129 (98.3) | 1607 (98.3) | 850 (97.6) | 1.93 (0.382) |
| Novel oral anticoagulants | 5 (0.2) | 3 (0.2) | 7 (0.8) | 7.86 (0.020) |
| PCSK9 inhibitor | 4 (0.2) | 3 (0.2) | 1 (0.1) | 0.20 (0.905) |
| Median (IQR) length of stay, days | 4.0 (3.0–4.0) | 4.0 (3.0–4.0) | 4.0 (3.0–4.0) | 1.96 (0.319)** |
| Deaths (%) | 31 (1.43) | 16 (0.98) | 7 (0.81) | 2.83 (0.243) |
#Statistics: χ2 test for categorical data; *unpaired t-test for continuous variables; **Kruskal-Wallis h-test for non-parametric data.
ACE angiotensin converting enzyme; ARB angiotensin receptor blockers; CAD coronary artery disease; HDL high density lipoprotein; IQR interquartile range; PCI percutaneous intervention; STEMI ST-elevation myocardial infarction; UAP unstable angina pectoris.
Fig. 2Management of ST-elevation myocardial infarction (STEMI) patients (n = 1985) among the uninsured and in various insurance groups.
Fig. 3In-hospital deaths (%) in the uninsured and government and privately insured patients. Unadjusted, age-sex-risk factor adjusted and multivariate adjusted odds ratios and 95% confidence intervals in the government and privately insured patients compared to the uninsured are shown.
Direct cost of hospitalization and other expenses in different insurance groups (US dollars median, IQR)a.
| Uninsured (n = 2166) | Government Insurance (n = 1635) | Private insurance (n = 871) | |||
|---|---|---|---|---|---|
| Total (n = 1635) | Regular government insurance (n = 1534) | Subsidized government insurance (n = 101) | |||
| Total cost of hospitalization | 2240 (1877–2783) | 1977 (1653–2437) | 2001 (1689–2478) | 1040 (785–1495) | 2013 (1668–2633) |
Hospital services | 900 (707–1068) | 809 (587–1007) | 833 (617–1018) | 160 (9–344) | 838 (573–1028) |
Disposables, stents and medicine | 1299 (950–1798) | 1276 (956–1733) | 1308 (993–1779) | 808 (679–959) | 1324 (933–1822) |
| 167,982 (140,705–208761) | 148,268 (124,000–182,802) | 150,047 (125,167–185,894) | 78,000 (58,850–112,119) | 150,940 (125,103–197,469) | |
Prices in US dollars, for conversion to Indian rupees multiply by 75; **Kruskal-Wallis h-test, p < 0.001 for inter-group comparisons.